Interpretations of elevated blood levels of alanine aminotransferase (ALT) for drug-induced liver injury often 18 assume that the biomarker is released passively from dying cells. However, the mechanisms driving that 19 release have not been explored experimentally. The usefulness of ALT and related biomarkers will improve 20 by developing mechanism-based explanations of elevated levels that can be expanded and elaborated 21 incrementally. We provide the means to challenge the ability of closely related concretized model mechanisms Page 3 of 33 48 individual mice and the virtual causal processes occurring during model execution are strongly analogous 49 within and among real hepatic lobular levels. 50
to generate patterns of simulated hepatic injury and ALT release that scale (or not) to be quantitatively similar 23 to the wet-lab validation targets. The validation targets for this work are elevated measures of plasma ALT 24 following acetaminophen (APAP) exposure in mice. We build on a published model mechanism that helps 25 explain the generation of characteristic spatiotemporal features of APAP hepatotoxicity within hepatic lobules.
26
Discrete event and agent-oriented software methods are most prominent. We instantiate and leverage a small 27 constellation of concrete model mechanisms. Their details during execution help bring into focus ways in 28 which particular sources of uncertainty become entangled within and across several levels with cause-effect 29 details. Monte Carlo sampling and simulations comprise a virtual experiment. Falsification of one (or more) 30 of the model mechanisms provides new knowledge and shrinks the model mechanism constellation 31 incrementally. We challenge the sufficiency of four potentially explanatory theories for ALT release. The 32 first model mechanism tested failed to achieve the initial validation target, but each of the three others 33 succeeded. We scale ALT amounts in virtual mice directly to target plasma ALT measures in individual mice.
34
Results for one of the three model mechanisms matched all target ALT measures quantitatively. We assert that 35 the actual mechanisms responsible for ALT measures in individual mice and the virtual causal processes 36 occurring during model execution are strongly analogous within and among real hepatic lobular levels.
37
Author summary 38 Interpretations of elevated biomarkers for drug-induced liver injury assume passive release during 39 hepatocyte death, yet indirect evidence indicates that plasma levels can increase absent injury. Limitations 40 on measurements make it infeasible to resolve causal linkages between drug disposition and plasma levels 41 of biomarkers. To improve explanatory knowledge, we instantiate within virtual mice, plausible 42 mechanism-based causal linkages between acetaminophen disposition and alanine aminotransferase 43 (ALT) behavior that enables simulation results to meet stringent quantitative validation prerequisites. We 44 challenge the sufficiency of four model mechanisms by scaling ALT measurements in virtual mice to 45 corresponding plasma values. Virtual experiment results in which ALT release is a combined 46 consequence of lobular-location-dependent hepatocyte death and drug-induced cellular damage, matches 47 all validation targets. We assert that the actual mechanisms responsible for plasma ALT measures in Introduction 51 The use of several conventional clinical biomarkers (e.g., alanine aminotransferase (ALT), aspartate 52 aminotransferase, creatine kinase, lipase, cardiac troponin, etc.) assumes that the analytes are passively 53 released from dying cells [1, 2] . However, the mechanisms have not been resolved experimentally. We 54 seek improved understanding of the temporal events leading to and driving biomarker release to aid their 55 interpretation, especially in cases where biomarker measures may be linked to medications, and to inform 56 the identification, validation, and use of future biomarkers. We begin by focusing on ALT release from 57 parenchymal cells (hepatocytes) in the liver. ALT is a good candidate for developing plausible release reported a 9-to 20-fold variation in mean serum ALT among different mouse strains that received a 69 standard toxic APAP dose. 70 The main objective of this work is to develop, support, and challenge plausible cause-effect linkages 71 between APAP disposition and metabolism and concurrent measurements of ALT in plasma. Doing Multi-source uncertainties have proven to be a stubborn barrier to progress in explaining ALT release. 81 The underlying novel advantage provided by the approach and methods that we employ is the ability to 82 represent both knowledge and ignorance concurrently by employing multiple computational methods. 83 Discrete event and agent-oriented software methods are most prominent. We instantiate in software and 84 leverage a small constellation of concrete model mechanisms that we intend to be strongly analogous to 85 actual in vivo counterparts. We use the model mechanisms illustrated in Fig. 1 and features are independent of APAP because the mouse counterparts of nonMD and MitoD can be 113 generated in many ways. 114 Model mechanism details during execution help bring into focus ways in which particular sources of 115 uncertainty become entangled with cause-effect details. Repetitive executions comprise an experiment, 116 which challenges the hypothesis that a particular model mechanism will achieve prespecified target [7, 9, 10 ]. The first model mechanism limits ALT release to necrotic cells. It failed to achieve the 124 initial validation target, but each of the three other mechanisms succeeded. These included a second, 
Results

141
The same parent Hepatotoxicity Mechanism for all experiments 142 A virtual experiment is a test (a trial) of an extant model mechanism (MM) hypothesis (see Model 143 mechanism requirements). To distinguish virtual mouse components, characteristics, and phenomena 144 from real counterparts, we capitalize the former hereafter and, in three cases, append the prefix "v". 145 Names of parameters are italicized.
Page 6 of 33 146 We used a parameterized version of the MM illustrated in Fig . Parameterizations for all key features are listed in Supporting S1 Table. Achieving the 156 validation targets for this work without having to alter the parent MM will strengthen the case that it is 157 strongly analogous to the actual APAP-induced hepatotoxicity mechanism. However, failure to achieve 158 those validation targets risks falsifying the parent MM.
159
Two ALT release processes: one confirmed, the other plausible 160 Evidence suggests externalization of damaged macromolecules is a normal, ongoing hepatocyte process. 161 Additional externalization processes may (or not) be engaged as rates of damage product accumulation 162 increase and the nature of those products change. Consequently, undamaged macromolecules such as 163 ALT may become coupled to one or more of these processes and become externalized directly or 164 concomitantly. 165 The parsimonious working hypothesis, illustrated in Fig reported that, following a low toxic APAP dose, APAP-protein adducts are externalized to blood prior to 175 ALT elevations. 176 We conjectured that instantiating a virtual counterpart to non-necrotic ALT release processes (see The initial value of the ALT counter is 5. As stated above, using ALT objects per vHPC = 5 proved 240 sufficient for this work. We could have added five ALT objects to each vHPC at t = 0. Although not 241 biomimetic, creating ALT objects as they are needed is computationally more efficient. Tracking objects 242 in all vHPCs that are doing nothing is computationally inefficient and increases the duration of 243 executions. Once an ALT externalization is scheduled, it will occur at that time if the ALT counter value induced hepatotoxicity, and we hypothesize that, when responding to a comparably toxic APAP dose, a 264 common set of entangled mechanism features governs ALT release and its subsequent accumulation in 265 plasma. 266 To acknowledge the variability within and between studies, we specified that the upper edge of the target 267 region shall include the mean plus the value of 1 standard-error-of-the-mean for the 3-to-6 plasma ALT 268 measures. We also specified that the lower edge of the target region shall include the mean minus the 269 value of 1 standard-error-of-the-mean of those values. (Fig. 3C ) are more dramatic than those for APAP because the fraction of APAP that is Metabolized 304 to NAPQI, rather than to G and S Metabolites, increases PP-to-PC (Fig. 1F) . Figure 3D 365 We continued using that range for the duration of this work. 366 Although the disposition of APAP and the occurrence of Damage was identical among the four MMs, 367 ALT release was different (Fig. 4A) . profile is the cumulative percent of ALT that was scheduled for release at t or earlier. Once an ALT is 386 scheduled for release, the event will occur following a Monte Carlo sampled Lag-Time.
387
Individualized model mechanism-based explanation for plasma ALT measures 388 From an APAP hepatotoxicity perspective, we reasoned that MitoD-Model is marginally more 389 parsimonious than nonMD-Model because MitoD production, rather than nonMD production, is directly (Fig. 6, C and D) . MitoD-Model is clearly an inadequate explanatory MM for results of both low and high 440 dose experiments. However, while keeping the parameterization of parent MM features (Fig. 1, A-F Delay are sensitive to unidentified non-genetic influences, such as environmental stressors (e.g., within-503 cage conflict). Such influences limit the reliability of ALT as a biomarker of drug-induced liver injury 504 and likely contribute to interindividual variability. They may also help explain elevated plasma ALT 505 measures absent toxicity. 506 We limited explorations to extensions of the parent No-ALT-Model (Fig, 1A-1F and Fig. 3 ) that were 507 suggested by hypothetical mechanistic scenarios described in the cited literature. By doing so, we 508 constricted to a manageable size the constellation of plausible MMs that merited exploration while 509 adhering to the strong parsimony guideline. It is noteworthy that we achieved the stringent validation Given the results presented, we extend that claim: at comparable levels of mechanism granularity, the 514 actual spatiotemporal mechanisms causing APAP-induced hepatic injuries in the test mice and giving rise 515 to the targeted plasma ALT measures were strongly analogous to mechanism counterparts within MitoD- 516 Model during execution. 517 The explanatory power of MitoD-Model following the medium APAP Dose (scales to 300 mg/kg in 518 mice) is significantly eroded for Doses corresponding to 150 and 600 mg/kg of APAP (Fig. 6 ), indicating 519 that the unfolding and entanglement of crucial temporal features of the mechanism (II) in mice is 520 predicated on APAP dose. 521 We detailed general weaknesses, limitations, strengths, and benefits of both the approach and methods in 522 previous reports [9, 21, 22] . Reliance on analogical arguments and reasoning is both a limitation and 523 strength. Bartha [23] summarizes recent advances in the use of analogical arguments in science and 524 provides guidelines for assessing their strengths and limitations. Because of in vivo measurement 525 limitations, a lack of detailed mechanism-based knowledge, and the fog of multi-source uncertainties, 526 reliance on analogical reasoning and arguments is necessary to make progress in achieving a key 527 objective, which is to begin resolving cause-effect linkages between APAP disposition and simultaneous 528 measurements of ALT in plasma. Because of uncertainties and knowledge gaps, there is still a significant 529 constellation of MMs having similar granularities that meet Requirements (see Model mechanism 530 requirements) and are capable of providing equally plausible quantitative explanations of APAP-induced 531 plasma ALT measures in mice. 532 Consequently, establishing a reliable reverse mapping from ALT measures to particular mechanism 533 features (I and II) is not yet feasible, and that reality limits the ability of ALT to serve as a mechanism- Although the magnitude of each scaling in Fig. 5 differs, the temporal patterns are the same. Most of the 552 events (II) driving ALT externalization are completed within the first 3 h (Fig. 3) . Consequently, we 553 expect that having sequential measures of plasma ALT from each mouse within 3-6 h post-dose will be 554 most effective in challenging those features. The results will also aid in resolving uncertainties grounded 555 in interindividual variability. Tightly coupling wet-lab and virtual experiments is scientifically sound and 556 is an economical way to concurrently expand explanatory knowledge while chipping away at those 557 uncertainties [7, 9, 21] . 558 The amount of ALT within each vHPC that can be externalized can be another target for falsification. 559 Absent evidence to the contrary, we specified that the amount is the same, independent of PV-to-CV 560 location 
Dose-response comparisons: ALT-in-Mouse-Body and plasma ALT measures
Materials and Methods
592
Experimental design 593 The objective of this work is to posit plausible cause-effect linkages between APAP disposition and 594 metabolism and concurrent measurements of ALT in plasma. Until sublobular hepatocyte damage and 595 ALT release can be measured concurrently at multiple times within the same subject, it will be infeasible 596 to establish those linkages in vivo. The alternative approach developed herein is to use virtual 597 experiments to challenge and falsify (or not) many potentially explanatory, biomimetic concretized MM-Page 20 of 33 598 based hypotheses [22] (see Model mechanism requirements). A virtual experiment is a test (a trial) of an 599 extant MM. The approach is based on analogical reasoning [23] . Execution produces an observable 600 mechanism. A consequence of execution that meets the requirements described below is emergence of 601 phenomena that are similar (or not) to prespecified target phenomena, such as pericentral necrosis and 602 ALT externalization. Execution produces a simulation with features that we can measure; those 603 measurements enable testing the hypothesis. If similarities between measures of virtual and real 604 phenomena meet a prespecified Similarity Criterion, then the MM during execution stands as a 605 challengeable yet tested MM-based theory about abstract, plausible mechanism events that may have 606 occurred during the wet-lab experiments. 607 We experiment on virtual Mice. Their concrete components are strongly analogous to mouse counterparts 608 within and across multiple levels, but only to the extent needed to achieve use objectives and Similarity Because of multisource uncertainties, to achieve the objective it is essential to conduct many narrowly 616 focused virtual experiments to incrementally and systematically shrink the constellation of plausible MM 617 parameterizations capable of achieving validation targets and Similarity Criteria. To do so, we follow an 618 Iterative Refinement Protocol [20, 28, 29] , which is a scientific method for falsifying, refining, and 619 validating explanatory MMs. 620 The Iterative Refinement Protocol begins with a MM, such as the No-ALT-Model, which has achieved 621 several validation targets. We then specify an enhanced Similarity Criterion, or a new feature or 622 phenomenon (e.g., accumulation of ALT-in-Mouse-Body). The immediate goal is that, when scaled, 623 results of executions mimic the validation target sufficiently to satisfy a Similarity Criterion (e.g., the time 
